The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) also said patients could switch to a non-oral contraceptive method. The guidance applies to Mounjaro, a diabetes and weight-loss drug, and is intended to help ensure contraception remains effective.

Eli Lilly will share the advice with healthcare professionals after a decision by the European Commission, the CHMP said. Women who can become pregnant and use Mounjaro are recommended to use contraception.

The committee assesses the quality, safety and efficacy of medicines in the European Union and issues recommendations to the European Commission. It said information on tirzepatide’s effect on oral contraceptive efficacy remains limited for women with obesity, overweight or type 2 diabetes mellitus.